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Objective: To emphasize that complex regional pain syndrome
(CRPS), a disabling disorder with the implication of aberrant
inflammation, vasomotor dysfunction, and maladaptive neuro-
plasticity, might be treated with a high dose of intravenous
immunoglobulin infusions (IVIG).
Methods: We describe a patient who presented with CRPS in the
acute phase of the disease.
Results: The CRPS developed secondary to sciatic compression in a
young patient and was treated within 10 days by high-dose IVIG
(2 g/kg). It resolved completely within days after infusions.
Discussion: This observational study emphasizes that high-dose
IVIG may be a treatment option in the acute phase of CRPS.
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Complex regional pain syndrome (CRPS) is a painfuldisorder characterized by a continuing regional pain
with various combinations of abnormal sensory, motor,
sudomotor, vasomotor, and trophic changes.1 The field has
deviated from the traditional use of the CRPS-1/CRPS-2
dichotomy, underscoring the implication of aberrant
inflammation, vasomotor dysfunction, and maladaptive
neuroplasticity in the development of this disabling dis-
order. Even though the precise etiology of the CRPS is
unknown, it is associated with an exaggerated inflamma-
tory response with distinct profile characteristics between
the acute and chronic form.2 According to the autoimmune
hypothesis, with the identification of functionally active
autoantibodies in certain CRPS patients,3 a recent
randomized controlled trial of low-dose (0.5 g/kg) intra-
venous infusions of human immunoglobulins (IVIG)
showed significantly reduced pain intensity in the treated
group among 13 chronic CRPS patients.4 We recently
encountered a young disabled CRPS patient and treated
him immediately with IVIG. The improvement was so
significant that the case is briefly reported here, emphasiz-
ing that IVIG might also be a promising therapeutic
alternative in the acute phase of the disorder.
CASE REPORT
D.C. is a 19-year-old man who recovered from a 7-hour
duration mandibular osteotomy with a right foot drop. Serum
creatine kinase levels were elevated (3700U/L, normal <200).
Examination revealed a right MRC grade 4 muscle weakness of the
extensors of the foot and toes, a right Achilles areflexia, as well as
hypoesthesia of the whole right foot. Electrodiagnostic studies
revealed a nonhomogenous motor and sensory axonal loss of the
right sciatic nerve. Two weeks later, the patient reported hyper-
algesia and neuropathic pain of the entire right leg with mechanical
hypersensitivity, edema, and erythema of the feet (Fig. 1). In line
with the “Budapest” criteria,5 CRPS was diagnosed. As maximal
dosage of pregabalin and tramadol did not reduce the intensity of
the pain, infusions of IVIG (total dose of 2 g/kg) were given over 4
days. Within the first day of the IVIG treatment, pain decreased
continuously and 2 weeks after the CRPS onset (1mo after surgery),
the pain and skin manifestations completely disappeared with a
slight residual muscle weakness of the foot extensor. Soon after, he
took up his employment and had no further functional restrictions.
CONCLUSIONS
The most likely diagnosis for the patient is post-
surgical compressive sciatic neuropathy with secondary
CRPS. The elevated creatine kinase levels and the long
operation in reclined position in a slim patient make a
postsurgical inflammatory neuropathy, in this context,
unlikely.6 The role of the posttraumatic inflammation
mediated by proinflammatory cytokines and neuropeptides
FIGURE 1. Image of the patient 2 weeks after the surgery,
demonstrating features of acute CRPS of the right foot, with
swelling and hyperemia.
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such as substance P is well documented in CRPS,1 and this
pathway might be the target of the beneficial action of
IVIG. It is believed that IVIG counteracts the ongoing
neuroinflammation by multiple mechanisms such as Fc-recep-
tor blockade, inhibition of complement deposition, neutrali-
zation of cytokines and growth factors, acceleration of auto-
antibodies clearance, as well as the activation of regulatory
macrophages and T cells through the FcgRIIb receptor.7,8
However, there is still limited evidence of IVIG treatment for
CRPS and the timing, therapeutic doses, and duration of IVIG
infusions are not yet known in CRPS.
Our reported patient underscores that early and high
IVIG doses (2 vs. 0.5 g/kg) might speed the healing of this
disabling disease in some patients. Further multicenter tri-
als are necessary to determine who should receive IVIG.
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